Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab - Yamaguchi, O; Kaira, K; Shinomiya, S (Thorac Cancer, 2021)